Cannabidiol: clinical trials recruiting now
9
Recruiting trials
15
Conditions studied
4
US states with sites
3
Countries
FDA drug label
- FDA-approved
- Yes. Cannabidiol appears in the FDA drug-label database. Marketed as Epidiolex.
- Mechanism of action
- Cytochrome P450 2C8 Inhibitors; Cytochrome P450 2C9 Inhibitors; Cytochrome P450 2C19 Inhibitors; UGT1A9 Inhibitors; UGT2B7 Inhibitors; Cytochrome P450 1A2 Inhibitors; Cytochrome P450 2B6 Inhibitors; Cytochrome P450 2B6 Inducers (as stated on the FDA label)
FDA-approved use
EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients 1 year of age and older. EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients 1 year of age and older ( 1 )
Phase breakdown
Phase 1 2
Phase 2 7
Phase 3 1
Phase 4 1
Conditions being studied
Recruiting trials involving Cannabidiol
- Assessing the Impact of Cannabidiol for Anxiety and Depression in Bipolar Disorder
- CBD for Individuals at Risk for Alzheimer's Disease
- Cannabidiol for Bipolar Depression (CBD-BD)
- Cannabidiol for Pain Relief of Patients With End-stage mCRPC
- Cannabidiol in Sickle Cell Disease
- Evaluating the Impact of a Novel Cannabinoid Product for Endometriosis
- Investigating the Effects of Cannabidiol on Social Anxiety Disorder
- Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors
- Study of Cannabidiol and Neuroimaging on Stress
Common questions
Is Cannabidiol FDA-approved?
Yes, marketed as Epidiolex.
How many recruiting trials involve Cannabidiol?
9 recruiting trials across 15 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.